908131-39-5

Basic information

• Product Name: lithium 1-[2-(tritylthio)ethyl]-1H-imidazole-2-carboxylate
• Synonyms: lithium 1-[2-(tritylthio)ethyl]-1H-imidazole-2-carboxylate
• CAS NO: 908131-39-5
• Molecular Weight: 420.461
• Mol File: 908131-39-5.mol

Chemical Properties

• CAS DataBase Reference: lithium 1-[2-(tritylthio)ethyl]-1H-imidazole-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: lithium 1-[2-(tritylthio)ethyl]-1H-imidazole-2-carboxylate(908131-39-5)
• EPA Substance Registry System: lithium 1-[2-(tritylthio)ethyl]-1H-imidazole-2-carboxylate(908131-39-5)

Safety Data

• Hazardous Substances Data: 908131-39-5(Hazardous Substances Data)

Upstream product

• 76-02-8 trifluoroacetyl chloride 
• 3695-77-0 triphenylmethanethiol 
• 157522-54-8 2-bromoethyl triphenylmethyl sulfide 

Relevant articles and documents

GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE

This invention provides peptides with novel modifications that provide suitable derivatization sites to improve the pharmacokinetic properties of the peptides. These GLP-1 modified peptides function in vivo as agonists of the GLP-1 receptor. The peptides of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, for example, type 2 diabetics.

GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE

This invention provides peptides with novel modifications that provide suitable derivatization sites to improve the pharmacokinetic properties of the peptides. These modified peptides function in vivo as agonists of the GIP receptor. The peptides of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, for example, type 2 diabetics.

PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE (PACAP) RECEPTOR (VPAC2) AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE

This invention provides peptides with novel modifications that provide suitable derivatization sites to improve the pharmacokinetic properties of the peptides. These modified peptides function in vivo as agonists of the VPAC2 receptor. The peptides of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, for example, type 2 diabetics.

NEUROPEPTIDE Y4 RECEPTOR AGONISTS

This invention provides peptides that act as selective NPY4 receptor agonists in vitro and are efficacious in vivo to reduce food intake. The invention is a peptide selected from a specific group of derivatized PP-related peptides, or functional equivalents thereof. The invention is also directed to a method of treating a metabolic disease in a mammal comprising administering a therapeutically effective amount of the peptides to said mammal to reduce food intake and body weight.